OSCR
Oscar Health, Inc.
OSCR has the edge over PTCT overall, supported by stronger fundamentals and stronger modeled upside.
PTCT
PTC Therapeutics, Inc.
PTCT has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PTCT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Strong |
PTCT's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
PTCT PE Valuation
PTCT has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PTCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for PTCT, with profitability improving. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over PTCT on earnings quality, reporting a profit while its opponent remains loss making.
PTCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.93 | — |
| Q3 2026 | -$1.36 | -116% |
| Q2 2026 | -$0.54 | -108% |
| Q1 2026 | -$2.29 | -135% |
| Q4 2025 | $7.78 | +$12.51 |
| Q3 2025 | $8.56 | +$14.51 |
| Q2 2025 | $6.97 | +$13.29 |
| Q1 2025 | $6.51 | +$14.20 |
| Q4 2024 | -$4.73 | +$3.64 |
PTCT has swung to a loss: it lost $1.36 per share over the past year, after a profit the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PTCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
PTCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $357.8M | +70% |
| Q2 2026 | $360.5M | +102% |
| Q1 2026 | $272.6M | -77% |
| Q4 2025 | $164.7M | -23% |
| Q3 2025 | $211M | +7.2% |
| Q2 2025 | $178.9M | -4.2% |
| Q1 2025 | $1.2B | +460% |
| Q4 2024 | $213.2M | -31% |
PTCT's revenue is recovering but still below its 2025 peak: $358M last quarter, up 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | +5.6 points |
| Q2 2026 | 41% | +61 points |
| Q1 2026 | 17% | -66 points |
| Q4 2025 | -43% | +33 points |
| Q3 2025 | 1.4% | +29 points |
| Q2 2025 | -20% | +2 points |
| Q1 2025 | 83% | +104 points |
| Q4 2024 | -76% | -78 points |
PTCT has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
PTCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28M | +$41.8M |
| Q2 2026 | $126.9M | +$186.6M |
| Q1 2026 | -$60.2M | -107% |
| Q4 2025 | -$36.6M | -$2.9M |
| Q3 2025 | -$69.7M | +$7.8M |
| Q2 2025 | -$59.7M | +$4.4M |
| Q1 2025 | $868.4M | +1320% |
| Q4 2024 | -$33.8M | +$72.1M |
PTCT has burned cash in almost every quarter: $2M over the past year, down 100% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PTCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -9.3% | -8.5M shares |
| 1 year | -4.2% | -3.6M shares |
| 3 years | +11% | +8.1M shares |
| 5 years | +18% | +12.9M shares |
| Available history | +42% | +24.6M shares |
PTCT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over PTCT on leverage, with a lower net debt burden relative to earnings.
PTCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -2.5x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q3 2024 | -15.8x | Net Cash |
| Q2 2024 | -51.7x | Net Cash |
PTCT's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PTCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 24.9 | Neutral |
PTCT's weekly RSI is 44 (neutral) and its Stochastic is 25 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PTCT PE vs Healthcare Sector
| Metric | PTCT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PTCT has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PTCT on trend strength, trading above more of its moving averages.
PTCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.4 | 1.5% above |
| 20 week MA | $68.8 | 7.9% below |
| 50 week MA | $70.9 | 11% below |
| 100 week MA | $62.3 | 1.7% above |
| 200 week MA | $49.1 | 29% above |
PTCT's trend is mixed: it's above three of its five weekly moving averages, and 29% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PTCT on returns for 2026, with the stronger performance.
PTCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.8 | $65.1 | +33% |
| 2021 | $65.1 | $41.9 | -36% |
| 2022 | $41.9 | $36.5 | -13% |
| 2023 | $36.5 | $27.6 | -24% |
| 2024 | $27.6 | $45.2 | +64% |
| 2025 | $45.2 | $78.6 | +74% |
| 2026 YTD | $78.6 | $63.4 | -19% |
PTCT has finished lower in three of the last six years. It's down 19% so far in 2026.